TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Have symptomatic AF of 3 to 48 hours duration at baseline.~* Be eligible for cardioversion.~* Have adequate anticoagulation therapy for cardioversion in accordance with standard of practice as recommended by ACC/AHA/ESC guidelines \[1\].~* Be hemodynamically stable and have systolic blood pressure (BP) above 100 mmHg and less than 160 mmHg and diastolic BP less than 95 mmHg at screening and baseline.~Key Exclusion Criteria:~* Known or suspected prolonged QT or uncorrected QT interval of \>440 msec as measured at screening on a 12 lead ECG, familial long QT syndrome, or previous torsades de pointes, ventricular fibrillation; or sustained ventricular tachycardia (VT).~* Symptomatic bradycardia, sick sinus syndrome, or ventricular rate less than 50 beats per minute (bpm) as documented by 12-lead ECG at screening.~* A QRS interval \>140 msec.~* Atrial flutter.~* Significant valvular stenosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy or constrictive pericarditis.~* Documented previous episodes of second or third degree atrioventricular (AV) block.~* Had a myocardial infarction (MI), acute coronary syndrome or cardiac surgery within 30 days prior to entry into the study.~* Uncorrected electrolyte imbalance of serum potassium or magnesium. Both K+ and Mg2+ must be corrected prior to dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Vernakalant Injection:~In one infusion line, subjects will receive a 10-minute infusion of vernakalant followed by a 15-minute observation period, followed by an additional 10-minute infusion of vernakalant if required (if the subject is still in AF). To maintain blinding, a 60-minute infusion of placebo (D5W) will be administered in a second infusion line, followed by a maintenance infusion of placebo for a minimum of an additional 60 minutes.
- 2 (Type: ACTIVE_COMPARATOR): Amiodarone Injection:~In one infusion line subjects will receive a 60-minute infusion of amiodarone followed by a maintenance infusion of amiodarone over an additional 60 minutes. To maintain blinding, a 10-minute infusion of placebo (normal saline) will be administered in a second infusion line, followed by a 15 minute observation period, followed by a 10 minute infusion of placebo if the subject is still in AF.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrafiltration Versus Intravenous (IV) Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure: (UNLOAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients hospitalized with primary diagnosis of acute decompensated congestive heart failure (adCHF)~* Evidence of fluid overload as indicated by:~  1. pitting edema (2+) of lower extremities;~ 2. jugular venous distension;~ 3. pulmonary edema or pleural effusion;~ 4. ascites;~ 5. paroxysmal nocturnal dyspnea or 2-pillow orthopnea~Exclusion Criteria:~* Acute coronary syndrome~* Creatinine greater than 3.0~* Systolic blood pressure less than or equal to 90 mmHg~* Hematocrit greater than 45%~* Prior administration of IV vasoactive drugs in the emergency room (ER)~* Clinical instability requiring pressors during hospitalization~* Recent use of iodinated contrast material~* Severe concomitant disease expected to prolong hospitalization~* Sepsis~* On or requires renal dialysis~* Had a cardiac transplant~* Heparin allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Antioxidants on Oxygen Induced Vasoconstriction in Lipopolysaccharide (LPS) Induced Inflammatory Model in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men aged between 18 and 35 years, nonsmokers~* Body mass index between 15th and 85th percentile (Must et al. 1991)~* Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant~* Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant~* Normal ophthalmic findings, ametropia \< 3 Dpt~Exclusion Criteria:~* Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study~* Treatment in the previous 3 weeks with any drug, vitamins and minerals supplements as well~* Symptoms of a clinically relevant illness in the 3 weeks before the first study day~* History of hypersensitivity to the trial drug or to drugs with a similar chemical structure~* History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with, distribution, metabolism or excretion of study drugs~* Blood donation during the previous 3 weeks

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of the STAR Maneuver on UGRA Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers~* Right handed~* Aged 18 to 55~Exclusion Criteria:~* Any person who has prior knowledge about ultrasound imaging or regional anesthesia~* Any person who has prior experience with laparoscopy or biopsy~* Any person who has problems with depth of field or simple hand eye co-ordination task

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- STAR (Type: EXPERIMENTAL): Introductory training by video depicting 4 sequential maneuvers for reacquisition of needle image in ultrasound: see, tilt, align, rotate.
- ART (Type: ACTIVE_COMPARATOR): Introductory training with a video depicting 3 probe position aspects for reacquisition of needle image by ultrasound: alignment, rotation, tilt.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Dexmedetomidine on Oxygenation and Lung Mechanics in Morbidly Obese Patients Undergoing Bariatric Operations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Morbid obese (body mass index \> 40) with documented restrictive lung disease scheduled to bariatric operation.~Exclusion Criteria:~* Heart failure~* ِِِِArrhythmia~* Heart block~* Severe liver or kidney impairment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine group (Type: EXPERIMENTAL): Patients will receive either, Dexmedetomidine (Precedex, Hospira, Lake forest, IL, USA) in a dose of (1ug/Kg LBW) bolus followed by 0.5ug/Kg continuous infusion for one hour
- Control group (Type: PLACEBO_COMPARATOR): Patients will receive normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants of 2 months of age~* The legal identity certificate (birth/household register) and vaccination certificate of the participants can be provided, and the legal guardian can provide the legal identity certificate (identity card).~* Guardians are able to understand the experimental vaccine, volunteer to participate in the study and sign informed consent for participation.~* Guardians are capable of using thermometer, graduated scale, filling diary card and contact card.~* Participants are not vaccinated with polio vaccine and immunoglobulin (except for Hepatitis b specific immunoglobulin) after birth, no vaccination of live vaccine within 28 days before enrollment and no vaccination of inactivated vaccine within 14 days before enrollment.~* Participants or guardians are able to obey and follow all study instructions, complete all the monitoring, and cooperate to complete collection of blood sample.~* Axillary temperature ≤37℃~Exclusion Criteria:~* Allergic to any active substance, inactive substance or materials used during production such as kanamycin.~* Patients with fever or acute disease.~* Have thrombocytopenia or hemorrhagic diseases~* Patients undergoing immunosuppressive therapy or immunodeficiency~* Have uncontrolled epilepsy or other progressive neurological disorders~* Other situations that the investigator consider as non-eligible

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 3 Months
- Healthy Volunteers: t

Study Arms:
- Batch 1 of sIPV (Type: EXPERIMENTAL): The first commercial batch of sIPV
- Batch 2 of sIPV (Type: EXPERIMENTAL): The second commercial batch of sIPV
- Batch 3 of sIPV (Type: EXPERIMENTAL): The third commercial batch of sIPV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with acute coronary disease with clinical symptoms and at least electrocardiogram changes or cardiac enzymes elevated~Exclusion Criteria:~* Use of anticoagulants within 10 days with an international normalized ratio (INR) \> 1.5 or planned use during the hospitalisation period~* Administration of clopidogrel \> 75 mg prior to randomization~* Contraindication to clopidogrel or aspirin~* Active bleeding or significant risk of bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clopidogrel high dose treatment regimen + ASA high dose (Type: EXPERIMENTAL): None
- Clopidogrel high dose treatment regimen + ASA low dose (Type: EXPERIMENTAL): None
- Clopidogrel standard treatment regimen + ASA high dose (Type: ACTIVE_COMPARATOR): None
- Clopidogrel standard treatment regimen + ASA low dose (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. adults aged 18 to 55~2. a Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of ≥ 20 after ≥ 12 weeks of treatment with an established effective dose of an Selective Serotonin Reuptake Inhibitors or clomipramine and after ≥ 10 weeks of augmentation treatment with antipsychotics (risperidone at least 2 mg/day quetiapine at least 150 mg/day; olanzapine at least 5mg/day; haloperidol titrated at least 10 mg/day; aripiprazole at least 10 mg/day)~Exclusion Criteria:~1. a history of alcohol or substance abuse~2. current severe depressive symptoms, bipolar disorder, panic disorder, schizophrenia, or other psychiatric conditions~3. heart disease, arrhythmia, liver problems, including cirrhosis, seizures, glaucoma or serious medical disease~4. hoarding as only Obsessive Compulsive symptom~5. women of childbearing potential not using a medically acceptable contraceptive method.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- ondansetron (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Female Breast Cancer patients with primary invasive breast cancer, histologically confirmed by core needle biopsy, whose tumors are estrogen (ER) and / or progesterone (PgR) positive (Clinical Stage \*T2, T3, T4a,b,c, N0, M0)~2. Patients after menopause~3. Tumor measurable by clinical examination, mammography and ultrasound~4. Adequate bone marrow, renal and hepatic function~5. A life expectancy of at least 6 months.~Exclusion criteria:~1. Prior treatment with aromatase inhibitors or antiestrogens.~2. Uncontrolled endocrine disorders such as diabetes mellitus, confirmed hypo- or hyperthyroidism, Cushing´s Syndrome, Addison´s disease (treated or untreated), Patients with unstable angina, uncontrolled cardiac disease (e.g. Class II or IV New York Heart Association's Functional Classification).~3. Patients with tumors in both breasts, evidence of inflammatory breast cancer or distant metastasis~4. Patients who are eligible for breast conserving surgery.~5. Concomitant anti-cancer treatments such as chemotherapy, immunotherapy/biological response modifiers (BRM's), endocrine therapy (including steroids), bisphosphonate therapy and radiotherapy. Patients who have received HRT will NOT be excluded, provided that HRT is discontinued at least 2 weeks prior to entry into the study.~Other protocol defined inclusion/exclusion criteria may apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Letrozole (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comedone Extraction and Oral Doxycycline In The First Line Treatment of Moderate Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with moderate acne vulgaris based on clinical manifestation of face (20-100 comedones, 15-50 inflammatory lesions, and/or 30-125 total lesions)~* Age range of 15 to 50 years old~Exclusion Criteria:~* History of oral antibiotics consumption within 2 weeks preceding this study~* Usage of topical retinoid in less than previous 2 weeks~* History of systemic retinoid consumption within 3 months preceding this study~* Pregnant of breastfeeding women~* Consuming oral contraception during examination~* Drug allergy or skin manifestation due to side effect of moderate acne vulgaris first line therapy

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Doxycycline Group (Type: PLACEBO_COMPARATOR): Subjects were randomized to receive Doxycycline capsules. The capsules were taken once daily for 6 weeks and evaluated every 2 weeks.
- Comedone Extraction Group (Type: ACTIVE_COMPARATOR): Subjects were randomized to receive comedone extraction. Comedone extraction were done three times, and evaluated every 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 12 Versus 20 mL PCB for D&E Cervical Prep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women 18 and older~* Intrauterine pregnancy ≥16 weeks gestation~* English speaking competency~* Willing and able to sign consent forms~* Agree to comply with study procedures~Exclusion Criteria:~* Women less than 18 years of age~* IV conscious sedation~* Known allergy to study medication (lidocaine)~* Any women not meeting inclusion criteria above will be excluded from participation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 12 mL arm (Type: EXPERIMENTAL): Intervention:~* Syringe loaded with 12 mL of 1% lidocaine (120 mg); 22-gauge spinal needle~* 2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix~* The tenaculum is immediately placed at the previously injected site~* The remaining 10 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)~* No wait time between injection and dilator insertion
- 20 mL arm (Type: ACTIVE_COMPARATOR): Intervention:~* Syringe loaded with 20 mL of 1% lidocaine (120 mg); 22-gauge spinal needle~* 2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix~* The tenaculum is immediately placed at the previously injected site~* The remaining 18 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)~* No wait time between injection and dilator insertion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants who participated in base study P05714 (NCT00696878) and received at least one dose of corifollitropin alfa in base study P05714;~* Ongoing pregnancy confirmed by ultrasound at least 10 weeks after a fresh embryo transfer in base study P05714;~* Able and willing to give written informed consent.~Exclusion Criteria:~* None

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Women/Expectant Mothers - Corifollitropin Alfa 150 µg (Type: None): In base study P05714 (NCT00696878), up to 3 COS cycles were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of Gonadotropin Releasing Hormone (GnRH) antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin (\[rec\]hCG) (5,000-10,000 IU/250 µg). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone was administered for luteal phase support. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur. Participants with confirmed pregnancy at least 10 weeks after fresh embryo transfer in the base study were eligible for this follow-up study. In this follow-up study P05715, no study drugs were administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete